- Sensei Biotherapeutics announced new clinical results for **solnerstotug** in PD-(L)1 resistant tumors at the ESMO Congress 2025, with data cutoff as of **September 8, 2025**.  **[1829802_0001193125-25-242007_d223319dex991.htm:0]** 
- The higher **15 mg/kg dose cohort** demonstrated a **6-month progression-free survival (PFS) of 50%** in PD-(L)1 resistant patients, which compares favorably to historical benchmarks.  **[1829802_0001193125-25-242007_d223319dex991.htm:0]** 
- Solnerstotug exhibited a **favorable safety profile**, with only six cases of mild (Grade 1) cytokine release syndrome (CRS) observed across all patients treated to date, all in the 15 mg/kg dose cohort.  **[1829802_0001193125-25-242007_d223319dex991.htm:0]** 
- These results support the advancement of solnerstotug to **Phase 2 studies**, planned to begin in **2026** for Non-Small Cell Lung Cancer (NSCLC) and Merkel Cell Carcinoma (MCC), subject to FDA feedback and capital.  **[1829802_0001193125-25-242007_d223319dex991.htm:0]** **[1829802_0001193125-25-242007_d223319dex991.htm:2]**

Sensei Biotherapeutics Reports Positive Solnerstotug Clinical Results and Phase 2 Plans

- Sensei Biotherapeutics announced positive results from the dose expansion portion of its Phase 1/2 trial for **solnerstotug** in PD-(L)1 resistant tumors, presented at ESMO Congress 2025 on **October 17, 2025**.  **[1829802_efd35e5f0fde444c95c531b3c3658a48_1]** 
- The trial demonstrated a **6-month progression-free survival (PFS) of 50%** in the 15 mg/kg dose cohort for PD-(L)1 refractory patients, which compares favorably to historical benchmarks of 10-20%.  **[1829802_efd35e5f0fde444c95c531b3c3658a48_0]** **[1829802_efd35e5f0fde444c95c531b3c3658a48_1]** 
- Solnerstotug exhibited a **favorable safety profile**, with only six mild (Grade 1) cytokine release syndrome (CRS) events observed across all patients, all of which were manageable.  **[1829802_efd35e5f0fde444c95c531b3c3658a48_0]** **[1829802_efd35e5f0fde444c95c531b3c3658a48_2]** 
- The company plans to advance solnerstotug to **Phase 2 studies in 2026** for Non-Small Cell Lung Cancer (NSCLC) and Merkel Cell Carcinoma (MCC), with potential for accelerated approval in MCC.  **[1829802_efd35e5f0fde444c95c531b3c3658a48_0]** **[1829802_efd35e5f0fde444c95c531b3c3658a48_4]**

Sensei Biotherapeutics (SNSE)